FY2024 EPS Estimates for Natera Boosted by Leerink Partnrs

Natera, Inc. (NASDAQ:NTRA) – Analysts at Leerink Partnrs raised their FY2024 EPS estimates for Natera in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of ($1.61) per share for the year, up from their previous forecast of ($1.83). The consensus estimate for Natera’s current full-year earnings is ($1.96) per share. Leerink Partnrs also issued estimates for Natera’s Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.40) EPS.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.95) EPS.

A number of other equities analysts have also recently weighed in on the stock. UBS Group lowered their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. The Goldman Sachs Group upped their target price on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Piper Sandler reiterated an “overweight” rating and set a $150.00 price target on shares of Natera in a research report on Friday, September 13th. Craig Hallum upped their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $137.65.

Natera Trading Down 6.1 %

Shares of NTRA stock opened at $151.11 on Friday. The business’s fifty day moving average price is $126.71 and its 200 day moving average price is $115.09. The company has a quick ratio of 4.01, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera has a 1-year low of $52.01 and a 1-year high of $167.79.

Insider Activity at Natera

In other news, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the transaction, the insider now directly owns 284,741 shares in the company, valued at $36,324,409.37. This represents a 0.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. The trade was a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,881 shares of company stock valued at $3,733,983. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC raised its position in shares of Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after buying an additional 60,127 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Natera by 15.1% during the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after purchasing an additional 9,781 shares during the period. Natixis acquired a new stake in Natera during the 1st quarter worth approximately $758,000. Chartwell Investment Partners LLC raised its holdings in Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after buying an additional 11,362 shares during the period. Finally, Baader Bank Aktiengesellschaft purchased a new position in Natera in the second quarter valued at approximately $478,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.